Защитный барьер слизистой оболочки желудка и возможности лекарственной цитопротекции

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231 (25): 232–5.
2. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77 (3): 433–43.
3. Robert A, Nezamis JE, Lancaster C et al. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol 1983; 245 (1): G113–21.
4. Mozsik G. Gastric cytoprotection 30 years after its discovery by André Robert: a personal perspective. Inflammopharmacology 2010; 18 (5): 209–21.
5. Tarnawski A, Ahluwalia A, Jones MK. Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des 2013; 19 (1): 126–32.
6. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36 (2): 132–57.
7. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19 (3): 449–90.
8. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J 2016; 39 (1): 14–23.
9. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005; 96 (2): 94–102.
10. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017; 152 (4): 706–15.
11. Trifan A, Stanciu C, Girleanu I et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol 2017; 23 (35): 6500–15.
12. Lichtenberger LM. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 1999; 15 (6): 463–72.
13. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135 (1): 41–60.
14. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005; 288 (1): C1–19.
15. Hills BA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach. Am J Physiol 1983: 244: G561–G568.
16. Atuma C, Strugala V, Allen A et al. The adherent gastric mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280: G922–G929.
17. Ho SB, Takamura K, Anway R et al. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci 2004; 49: 1598–606.
18. Taylor C, Allen A, Dettmar PW, Pearson JP. The gel matrix of gastric mucus is maintained by a complex interplay of transient and nontransient associations. Biomacromolecules 2003; 4: 922–7.
19. Bell AE, Sellers LA, Allen A et al. Properties of gastric and duodenal mucus: effect of proteolysis, disulfide reduction, bile, acid, ethanol, and hypertonicity on mucus gel structure. Gastroenterology 1985; 88 (1, part 2): 269–80.
20. Newton J, Jordan N, Oliver L et al. Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier function is not compromised. Gut 1998; 43: 470–5.
21. Sidebotham RL, Batten JJ, Karim QN et al. Breakdown of gastric mucus in presence of Helicobacter pylori. J Clin Pathol 1991; 44 (1): 52–7.
22. Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and meta-analysis. World J Gastroenterol 2015; 21 (31): 9430–6.
23. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut 1999; 44: 890–5.
24. Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol 2017; 79: 357–80.
25. Phillipson M, Atuma C, Henriksnas J, Holm L. The importance of mucus layers and bicarbonate transport in preservation of gastric juxtamucosal pH. Am J Physiol Gastrointest Liver Physiol 2002; 282 (2): G2119.
26. Hunt RH, Camilleri M, Crowe SE et al. The stomach in health and disease. Gut 2015; 64 (10): 1650–68.
27. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an overview. Curr Gastroenterol Rep 2015; 17 (6): 24. DOI: 10.1007/s11894-015-0452-2
28. Lee H-J, Ock CY, Kim S-J, Hahm K-B. Heat shock protein: hard worker or bad offender for gastric diseases. Int J Proteomics 2010. DOI: 10.1155/2010/259163
29. Chiou SK, Tanigawa T, Akahoshi T et al. Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology. 2005; 128 (1): 63–73.
30. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32 (7): 519–27.
31. Palileo C, Kaunitz JD. Gastrointestinal defense mechanisms. Curr Opin Gastroenterol 2011; 27 (6): 543–8. DOI: 10.1097/MOG.0b013e32834b3fcb
32. Hoffmann W. Current Status on Stem Cells and Cancers of the Gastric Epithelium. Int J Mol Sci 2015; 16 (8): 19153–69.
33. Bartfeld S, Koo BK. Adult gastric stem cells and their niches. Wiley Interdiscip Rev Dev Biol 2017; 6 (2),: e261.
34. Jones MK, Tomikawa M, Mohajer B, Tarnawski AS. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci 1999; 4: D303–9.
35. Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol Paris 2001; 95 (1–6): 337–44.
36. Kosone T, Takagi H, Kakizaki S et al. Integrative roles of transforming growth factor-alpha in the cytoprotection mechanisms of gastric mucosal injury. BMC Gastroenterol 2006; 6: 22. DOI: 10.1186/1471-230X-6-22
37. Nguyen T, Chai J, Li A et al. Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner. Am J Pathol 2007; 170 (4): 1219–28.
38. Gannon B, Browning J, O’Brien P, Rogers P. Mucosal microvascular architecture of the fundus and body of the human stomach. Gastroenterology 1984; 86: 866–75.
39. Kawano S, Tsuji S. Role of mucosal blood flow: a conceptional review in gastric mucosal injury and protection. J Gastroenterol Hepatol 2000; 15 (Suppl.): D1–6.
40. Tarnawski AS, Ahluwalia A, Jones MK. The mechanisms of gastric mucosal injury: focus on microvascular endothelium as a key target. Curr Med Chem 2012; 19 (1): 4–15.
41. Brzozowski T, Konturek PC, Konturek SJ et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56 (Suppl. 5): 33–55.
42. Niv Y, Banic M. Gastric barrier function and toxic damage. Dig Dis 2014; 32 (3): 235–42.
43. Takahashi M, Maeda S, Ogura K et al. The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro. J Clin Gastroenterol 1998; 27 (Suppl. 1): S178–82.
44. Miura S, Tatsuguchi A, Wada K et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 2004; 287 (2): G444–51.
45. Martin GR, Wallace JL. Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) 2006; 231 (2): 130–7.
46. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88 (4): 1547–65.
47. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134 (7): 1842–60.
48. Alzahrani S, Lina TT, Gonzalez J et al. Effect of Helicobacter pylori on gastric epithelial cells. World J Gastroenterol 2014; 20 (36): 12767–80.
49. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99: 295–304.
50. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 59 (Suppl. 1): S24–33.
51. Tarnawski AS, Ahluwalia A. Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Update. Curr Medicinal Chem 2012; 19 (1): 16–27.
52. Tarnawski AS, Ahluwalia A, Jones MK. Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J Gastroenterol Hepatol 2014; 29 (Suppl. 4): 112–23.
53. Tarnawski A, Stachura J, Krause WJ et al. Quality of gastric ulcer healing – a new, emerging concept. J Clin Gastroenterol 1991; 13 (1): S42–7.
54. Tarnawski A, Douglass TG, Stachura J, Krause WJ. Quality of gastric ulcer healing: histological and ultrastructural assessment. Aliment Pharmacol Therap 1991; 5 (Suppl. 1): 79–90.
55. Аруин Л.И. Качество заживления гастродуоденальных язв: функциональная морфология. Роль методов патогенетической терапии. Эксперим. и клин. гастроэнтерология. 2006; 5: 40–9. / Aruin L.I. Kachestvo zazhivleniia gastroduodenal'nykh iazv: funktsional'naia morfologiia. Rol' metodov patogeneticheskoi terapii. Eksperim. i klin. gastroenterologiia. 2006; 5: 40–9. [in Russian]
56. Arakawa T, Watanabe T, Tanigawa T et al. Quality of ulcer healing in gastrointestinal tract: its pathophysiology and clinical relevance. World J Gastroenterol 2012; 18 (35): 4811–22.
57. Arakawa T, Higuchi K et al. Prostaglandins in the stomach: an update. J Clin Gastroenterol 1998; 27 (Suppl. 1): S1–11.
58. Kobayashi K, Arakawa T, Nakamura H et al. Protective action of endogenous prostacyclin (PGI2) and prostaglandin E2 (PGE2) in endoscopic polypectomy-induced human ulcers. Gastroenterol Jpn 1982; 17 (5): 430–3.
59. Arakawa T, Watanabe T, Fukuda T et al. Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins. Dig Dis Sci 1996; 41 (10): 2055–61.
60. Jones MK, Kawanaka H, Baatar D et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 2001; 121 (5): 1040–7.
61. Arakawa T, Kobayashi K. Quality of ulcer healing – a new concept to rank healed peptic ulcers. Gastroenterol Jpn 1993; 28 (Suppl. 5): 158–62.
62. Nebiki H, Arakawa T, Higuchi K, Kobayashi K. Quality of ulcer healing influences the relapse of gastric ulcers in humans. J Gastroenterol Hepatol 1997; 12 (2): 109–14.
63. Arakawa T, Watanabe T, Fukuda T et al. Ulcer recurrence: cytokines and inflammatory response-dependent process. Dig Dis Sci 1998; 43 (Suppl. 9): 61S–66S.
64. Ливзан М.А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori в постэрадикационном периоде. Эксперим. и клин. гастроэнтерология. 2007; 5: 116–23. / Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori v posteradikatsionnom periode. Eksperim. i klin. gastroenterologiia. 2007; 5: 116–23. [in Russian]
65. Musumba C, Jorgensen A, Sutton L et al. The relative contribution of NSAIDs and Helicobacter pylori to the etiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012; 36 (1): 48–56.
66. Genta RM, Sonnenberg A. Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (2): 218–26.
67. Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015; 30 (5): 559–70.
68. Shiota S, Thrift AP, Green L et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol 2017; 15 (7): 1037–46.
69. Szabo S. “Gastric cytoprotection” is still relevant. Gastroenterol Hepatol 2014; 29 (Suppl. 4): 124–32.
70. Hall DW, van den Hoven WE. Protective properties of colloidal bismuth subcitrate on gastric mucosa. Scand J Gastroenterol Suppl 1986; 122: 11–3.
71. Konturek SJ, Radecki T, Piastucki I et al. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 1987; 28 (2): 201–5.
72. Hinsull SM, Bellamy D. Effect of repeated colloidal bismuth subcitrate treatment on the response of the rat gastric mucosa to the presence of luminal ethanol. Gut 1990; 31 (4): 389–96.
73. Van den Hoven WE, Birtwhistle RD, Hall DW. Morphologic evaluation of gastric mucosal protection by colloidal bismuth subcitrate (De-Nol). Int J Tissue React 1988; 10 (5): 297–304.
74. Winters C, Hinsull SM, Gregory Z. A scanning electron microscopic morphological and semi-quantitative evaluation of rat stomach treated with colloidal bismuth subcitrate and alcohol. Scanning Microsc 1991; 5 (2): 541–7.
75. Konturek SJ, Bilski J, Kwiecien N et al. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism. Gut 1987; 28 (12): 1557–63.
76. Konturek SJ, Kwiecien N, Obtulowicz W et al. Effects of protective drugs on gastric alkaline secretion in man. Scand J Gastroenterol 1987; 22 (9): 1059–63.
77. Mertz-Nielsen A, Steenberg P, Neumark T et al. Colloidal bismuth subcitrate causes sustained release of gastric mucosal prostaglandin E2. Aliment Pharmacol Ther 1991; 5 (2): 127–33.
78. Estela R, Feller A, Backhouse C et al. Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2. Rev Med Chil 1984; 112 (10): 975–81.
79. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36 (2): 132–57.
80. Crampton JR, Gibbons LC, Rees WD. Effect of certain ulcer-healing agents on amphibian gastroduodenal bicarbonate secretion. Scand J Gastroenterol 1986; 21 (Suppl. 125): 113–8.
81. Shorrock CJ, Crampton JR, Gibbons LC, Rees WD. Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion. Gut 1989; 30 (7): 917–21.
82. Lee SP. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid. Scand J Gastroenterol Suppl 1982; 80: 17–21.
83. Tasman-Jones C, Maher C, Thomsen L et al. Mucosal defenses and gastroduodenal disease. Digestion 1987; 37 (Suppl. 2): 1–7.
84. Piotrowski J, Bilski J, Nishikawa H et al. Enhancement in gastric mucus gel qualities with colloidal bismuth subcitrate administration. Eur J Pharmacol 1990; 184 (1): 55–63.
85. Hollanders D, Morrissey SM, Mehta J. Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol). Br J Clin Pract 1983; 37 (3): 112–4.
86. Weiss G, Kallmeyer JC. Pilot trial of a colloidal bismuth preparation in the treatment of peptic ulcer. S Afr Med J 1968; 42 (13): 317–20.
87. Koo J, Ho J, Lam SK et al. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 1982; 82: 864–70.
88. Soutar RL, Coghill SB. Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro. Gastroenterology 1986; 91 (1): 84–93.
89. Konturek SJ, Dembinski A, Warzecha Z et al. Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats. Gut 1988; 29 (7): 894–902.
90. Slomiany BL, Nishikawa H, Bilski J, Slomiany A. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Am J Gastroenterol 1990; 85 (4): 390–3.
91. Konturek JW, Brzozowski T, Konturek SJ. Epidermal growth factor in protection, repair, and healing of gastroduodenal mucosa. J Clin Gastroenterol 1991; 13 (Suppl. 1): S88–97.
92. Konturek JW, Brzozowski T, Konturek SJ. Epidermal growth factor in protection, repair, and healing of gastroduodenal mucosa. J Clin Gastroenterol 1991; 13 (Suppl. 1): S88–97.
93. Eleftheriadis E, Kotzampassi K, Tzartinoglou E et al. Colloidal bismuth subcitrate-induced changes on gastric mucosal hemodynamics in the rat: gastric mucosal blood flow after CBS treatment. Gastroenterol Jpn 1991; 26 (3): 283–6.
94. Bagchi D, McGinn TR, Ye X et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci 1999; 44 (12): 2419–28.
95. Bagchi D, Carryl OR, Tran MX et al. Protection against chemically-induced oxidative gastrointestinal tissue injury in rats by bismuth salts. Dig Dis Sci 1997; 42 (9): 1890–900.
96. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88 (4): 1547–65.
97. Ahmed A, Salmon PR, Cairns CR et al. Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate. Gut 1992; 33 (2): 159–63.
98. Rokkas T, Pursey C, Uzoechina E et al. Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29 (10): 1386–91.
99. Loffeld RJ, Potters HV, Stobberingh E et al. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut 1989; 30 (9): 1206–12.
100. Kang JY, Tay HH, Wee A, Guan R et al. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 1990; 31 (4): 476–80.
101. Goh KL, Parasakthi N, Peh SC et al. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26 (11): 1123–31.
102. Vaira D, Holton J, Ainley C et al. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia. Ital J Gastroenterol 1992; 24 (7): 400–4.
103. Fischbach LA, Correa P, Ramirez H et al. Anti-inflammatory and tissue protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Aliment Pharmacol Ther 2001; 15 (6): 831–41.
104. Кононов А.В., Мозговой С.И., Рыбкина Л.Б. и др. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2014; 24 (6): 21–8. / Kononov A.V., Mozgovoi S.I., Rybkina L.B. i dr. Otsenka tsitoprotektivnogo vliianiia vismuta trikaliia ditsitrata na slizistuiu obolochku zheludka pri eradikatsii H. pylori. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (6): 21–8. [in Russian]
105. Рыбкина Л.Б., Назаров А.Н., Владимирова А.В. Клинико-морфологическое обоснование продолженной терапии препаратом висмута трикалия дицитратом при хроническом Helicobacter pylori-ассоциированном гастрите с синдромом диспепсии. Молодой ученый. 2015; 22 (102): 285–95. / Rybkina L.B., Nazarov A.N., Vladimirova A.V. Kliniko-morfologicheskoe obosnovanie prodolzhennoi terapii preparatom vismuta trikaliia ditsitratom pri khronicheskom Helicobacter pylori-assotsiirovannom gastrite s sindromom dispepsii. Molodoi uchenyi. 2015; 22 (102): 285–95. [in Russian]
106. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперим. и клин. гастроэнтерология. 2012; 5: 99–106. / Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
107. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep 2011; 16 (1): 1–7.
108. Kalisperati P, Spanou E, Pateras IS et al. Inflammation, DNA damage, Helicobacter pylori and gastric tumorigenesis. Front Genet 2017; 8: 20. DOI: 10.3389/fgene.2017.00020
109. Кононов А.В. Роль патологоанатомического заключения «Хронический гастрит» в системе персонифицированной канцерпревенции. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2018; 28 (4): 91–101. / Kononov A.V. Rol' patologoanatomicheskogo zakliucheniia "Khronicheskii gastrit" v sisteme personifitsirovannoi kantserpreventsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2018; 28 (4): 91–101. [in Russian]
110. Lee SP. The mode of action of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl 1991; 185: 1–6.
111. Beil W, Bierbaum S, Sewing KF. Studies on the mechanism of action of colloidal bismuth subcitrate. II. Interaction with pepsin. Pharmacology 1993; 47 (2): 141–4.
112. Baron JH, Barr J, Batten J et al. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 1986; 27 (5): 486–90.
113. Marshall BJ, Armstrong JA, Francis GJ et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987; 37 (Suppl. 2): 16–30.
114. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65 (5): 870–8.
115. Goodwin CS, Armstrong JA, Cooper M. Colloidal bismuth subcitrate inhibits the adherence of H. pylori to epithelial cells. Ital J Gastroenterology 1991; 23 (Suppl. 2): 40.
116. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии. Лечащий врач. 2014; 4: 73–9. / Maev I.V., Ku­cheriavyi Yu.A., Andreev D.N. Aktual'nye vozmozhnosti optimizatsii antikhelikobakternoi terapii. Lechashchii vrach. 2014; 4: 73–9. [in Russian]
117. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics 2012; 4 (3): 239–43.
118. Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther 2015; 42: 922–33.
119. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection Maastricht V/Florence Consensus Report. Gut 2016; 66: 6–30.
120. Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther 2016; 14 (6): 577–85.
121. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; e12392.
122. Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther 2018; 16 (9): 679–87.
123. Ивашкин В.Т., Маев И.В., Лапина Т.Л. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерологии, гепатологии и колопроктологии. 2012; 22 (1): 87–9. / Ivashkin V.T., Maev I.V., Lapina T.L. Rekomendatsii Rossiiskoi Gastroenterologicheskoi Assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2012; 22 (1): 87–9. [in Russian]
124. Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И. и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Эксперим. и клин. гастроэнтерология. 2017; 2 (138): 3–21. / Lazebnik L.B., Tkachenko E.I., Abdulganieva D.I. i dr. VI Natsional'nye rekomendatsii po diagnostike i lecheniiu kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (VI Moskovskie soglasheniia). Eksperim. i klin. gastroenterologiia. 2017; 2 (138): 3–21. [in Russian]
125. Sun H. Biological Chemistry of Arsenic, Antimony and Bismuth. USA, NJ: John Wiley & Sons: Hoboken, 2011.

________________________________________________

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231 (25): 232–5.
2. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77 (3): 433–43.
3. Robert A, Nezamis JE, Lancaster C et al. Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am J Physiol 1983; 245 (1): G113–21.
4. Mozsik G. Gastric cytoprotection 30 years after its discovery by André Robert: a personal perspective. Inflammopharmacology 2010; 18 (5): 209–21.
5. Tarnawski A, Ahluwalia A, Jones MK. Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des 2013; 19 (1): 126–32.
6. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36 (2): 132–57.
7. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19 (3): 449–90.
8. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J 2016; 39 (1): 14–23.
9. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005; 96 (2): 94–102.
10. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017; 152 (4): 706–15.
11. Trifan A, Stanciu C, Girleanu I et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol 2017; 23 (35): 6500–15.
12. Lichtenberger LM. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 1999; 15 (6): 463–72.
13. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135 (1): 41–60.
14. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005; 288 (1): C1–19.
15. Hills BA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach. Am J Physiol 1983: 244: G561–G568.
16. Atuma C, Strugala V, Allen A et al. The adherent gastric mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280: G922–G929.
17. Ho SB, Takamura K, Anway R et al. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci 2004; 49: 1598–606.
18. Taylor C, Allen A, Dettmar PW, Pearson JP. The gel matrix of gastric mucus is maintained by a complex interplay of transient and nontransient associations. Biomacromolecules 2003; 4: 922–7.
19. Bell AE, Sellers LA, Allen A et al. Properties of gastric and duodenal mucus: effect of proteolysis, disulfide reduction, bile, acid, ethanol, and hypertonicity on mucus gel structure. Gastroenterology 1985; 88 (1, part 2): 269–80.
20. Newton J, Jordan N, Oliver L et al. Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier function is not compromised. Gut 1998; 43: 470–5.
21. Sidebotham RL, Batten JJ, Karim QN et al. Breakdown of gastric mucus in presence of Helicobacter pylori. J Clin Pathol 1991; 44 (1): 52–7.
22. Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and meta-analysis. World J Gastroenterol 2015; 21 (31): 9430–6.
23. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut 1999; 44: 890–5.
24. Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol 2017; 79: 357–80.
25. Phillipson M, Atuma C, Henriksnas J, Holm L. The importance of mucus layers and bicarbonate transport in preservation of gastric juxtamucosal pH. Am J Physiol Gastrointest Liver Physiol 2002; 282 (2): G2119.
26. Hunt RH, Camilleri M, Crowe SE et al. The stomach in health and disease. Gut 2015; 64 (10): 1650–68.
27. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an overview. Curr Gastroenterol Rep 2015; 17 (6): 24. DOI: 10.1007/s11894-015-0452-2
28. Lee H-J, Ock CY, Kim S-J, Hahm K-B. Heat shock protein: hard worker or bad offender for gastric diseases. Int J Proteomics 2010. DOI: 10.1155/2010/259163
29. Chiou SK, Tanigawa T, Akahoshi T et al. Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology. 2005; 128 (1): 63–73.
30. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32 (7): 519–27.
31. Palileo C, Kaunitz JD. Gastrointestinal defense mechanisms. Curr Opin Gastroenterol 2011; 27 (6): 543–8. DOI: 10.1097/MOG.0b013e32834b3fcb
32. Hoffmann W. Current Status on Stem Cells and Cancers of the Gastric Epithelium. Int J Mol Sci 2015; 16 (8): 19153–69.
33. Bartfeld S, Koo BK. Adult gastric stem cells and their niches. Wiley Interdiscip Rev Dev Biol 2017; 6 (2),: e261.
34. Jones MK, Tomikawa M, Mohajer B, Tarnawski AS. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci 1999; 4: D303–9.
35. Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol Paris 2001; 95 (1–6): 337–44.
36. Kosone T, Takagi H, Kakizaki S et al. Integrative roles of transforming growth factor-alpha in the cytoprotection mechanisms of gastric mucosal injury. BMC Gastroenterol 2006; 6: 22. DOI: 10.1186/1471-230X-6-22
37. Nguyen T, Chai J, Li A et al. Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner. Am J Pathol 2007; 170 (4): 1219–28.
38. Gannon B, Browning J, O’Brien P, Rogers P. Mucosal microvascular architecture of the fundus and body of the human stomach. Gastroenterology 1984; 86: 866–75.
39. Kawano S, Tsuji S. Role of mucosal blood flow: a conceptional review in gastric mucosal injury and protection. J Gastroenterol Hepatol 2000; 15 (Suppl.): D1–6.
40. Tarnawski AS, Ahluwalia A, Jones MK. The mechanisms of gastric mucosal injury: focus on microvascular endothelium as a key target. Curr Med Chem 2012; 19 (1): 4–15.
41. Brzozowski T, Konturek PC, Konturek SJ et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56 (Suppl. 5): 33–55.
42. Niv Y, Banic M. Gastric barrier function and toxic damage. Dig Dis 2014; 32 (3): 235–42.
43. Takahashi M, Maeda S, Ogura K et al. The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro. J Clin Gastroenterol 1998; 27 (Suppl. 1): S178–82.
44. Miura S, Tatsuguchi A, Wada K et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol 2004; 287 (2): G444–51.
45. Martin GR, Wallace JL. Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) 2006; 231 (2): 130–7.
46. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88 (4): 1547–65.
47. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134 (7): 1842–60.
48. Alzahrani S, Lina TT, Gonzalez J et al. Effect of Helicobacter pylori on gastric epithelial cells. World J Gastroenterol 2014; 20 (36): 12767–80.
49. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99: 295–304.
50. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 59 (Suppl. 1): S24–33.
51. Tarnawski AS, Ahluwalia A. Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Update. Curr Medicinal Chem 2012; 19 (1): 16–27.
52. Tarnawski AS, Ahluwalia A, Jones MK. Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J Gastroenterol Hepatol 2014; 29 (Suppl. 4): 112–23.
53. Tarnawski A, Stachura J, Krause WJ et al. Quality of gastric ulcer healing – a new, emerging concept. J Clin Gastroenterol 1991; 13 (1): S42–7.
54. Tarnawski A, Douglass TG, Stachura J, Krause WJ. Quality of gastric ulcer healing: histological and ultrastructural assessment. Aliment Pharmacol Therap 1991; 5 (Suppl. 1): 79–90.
55. Aruin L.I. Kachestvo zazhivleniia gastroduodenal'nykh iazv: funktsional'naia morfologiia. Rol' metodov patogeneticheskoi terapii. Eksperim. i klin. gastroenterologiia. 2006; 5: 40–9. [in Russian]
56. Arakawa T, Watanabe T, Tanigawa T et al. Quality of ulcer healing in gastrointestinal tract: its pathophysiology and clinical relevance. World J Gastroenterol 2012; 18 (35): 4811–22.
57. Arakawa T, Higuchi K et al. Prostaglandins in the stomach: an update. J Clin Gastroenterol 1998; 27 (Suppl. 1): S1–11.
58. Kobayashi K, Arakawa T, Nakamura H et al. Protective action of endogenous prostacyclin (PGI2) and prostaglandin E2 (PGE2) in endoscopic polypectomy-induced human ulcers. Gastroenterol Jpn 1982; 17 (5): 430–3.
59. Arakawa T, Watanabe T, Fukuda T et al. Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins. Dig Dis Sci 1996; 41 (10): 2055–61.
60. Jones MK, Kawanaka H, Baatar D et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology 2001; 121 (5): 1040–7.
61. Arakawa T, Kobayashi K. Quality of ulcer healing – a new concept to rank healed peptic ulcers. Gastroenterol Jpn 1993; 28 (Suppl. 5): 158–62.
62. Nebiki H, Arakawa T, Higuchi K, Kobayashi K. Quality of ulcer healing influences the relapse of gastric ulcers in humans. J Gastroenterol Hepatol 1997; 12 (2): 109–14.
63. Arakawa T, Watanabe T, Fukuda T et al. Ulcer recurrence: cytokines and inflammatory response-dependent process. Dig Dis Sci 1998; 43 (Suppl. 9): 61S–66S.
64. Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori v posteradikatsionnom periode. Eksperim. i klin. gastroenterologiia. 2007; 5: 116–23. [in Russian]
65. Musumba C, Jorgensen A, Sutton L et al. The relative contribution of NSAIDs and Helicobacter pylori to the etiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther 2012; 36 (1): 48–56.
66. Genta RM, Sonnenberg A. Helicobacter-negative gastritis: a distinct entity unrelated to Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (2): 218–26.
67. Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015; 30 (5): 559–70.
68. Shiota S, Thrift AP, Green L et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol 2017; 15 (7): 1037–46.
69. Szabo S. “Gastric cytoprotection” is still relevant. Gastroenterol Hepatol 2014; 29 (Suppl. 4): 124–32.
70. Hall DW, van den Hoven WE. Protective properties of colloidal bismuth subcitrate on gastric mucosa. Scand J Gastroenterol Suppl 1986; 122: 11–3.
71. Konturek SJ, Radecki T, Piastucki I et al. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 1987; 28 (2): 201–5.
72. Hinsull SM, Bellamy D. Effect of repeated colloidal bismuth subcitrate treatment on the response of the rat gastric mucosa to the presence of luminal ethanol. Gut 1990; 31 (4): 389–96.
73. Van den Hoven WE, Birtwhistle RD, Hall DW. Morphologic evaluation of gastric mucosal protection by colloidal bismuth subcitrate (De-Nol). Int J Tissue React 1988; 10 (5): 297–304.
74. Winters C, Hinsull SM, Gregory Z. A scanning electron microscopic morphological and semi-quantitative evaluation of rat stomach treated with colloidal bismuth subcitrate and alcohol. Scanning Microsc 1991; 5 (2): 541–7.
75. Konturek SJ, Bilski J, Kwiecien N et al. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism. Gut 1987; 28 (12): 1557–63.
76. Konturek SJ, Kwiecien N, Obtulowicz W et al. Effects of protective drugs on gastric alkaline secretion in man. Scand J Gastroenterol 1987; 22 (9): 1059–63.
77. Mertz-Nielsen A, Steenberg P, Neumark T et al. Colloidal bismuth subcitrate causes sustained release of gastric mucosal prostaglandin E2. Aliment Pharmacol Ther 1991; 5 (2): 127–33.
78. Estela R, Feller A, Backhouse C et al. Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2. Rev Med Chil 1984; 112 (10): 975–81.
79. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36 (2): 132–57.
80. Crampton JR, Gibbons LC, Rees WD. Effect of certain ulcer-healing agents on amphibian gastroduodenal bicarbonate secretion. Scand J Gastroenterol 1986; 21 (Suppl. 125): 113–8.
81. Shorrock CJ, Crampton JR, Gibbons LC, Rees WD. Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion. Gut 1989; 30 (7): 917–21.
82. Lee SP. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid. Scand J Gastroenterol Suppl 1982; 80: 17–21.
83. Tasman-Jones C, Maher C, Thomsen L et al. Mucosal defenses and gastroduodenal disease. Digestion 1987; 37 (Suppl. 2): 1–7.
84. Piotrowski J, Bilski J, Nishikawa H et al. Enhancement in gastric mucus gel qualities with colloidal bismuth subcitrate administration. Eur J Pharmacol 1990; 184 (1): 55–63.
85. Hollanders D, Morrissey SM, Mehta J. Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol). Br J Clin Pract 1983; 37 (3): 112–4.
86. Weiss G, Kallmeyer JC. Pilot trial of a colloidal bismuth preparation in the treatment of peptic ulcer. S Afr Med J 1968; 42 (13): 317–20.
87. Koo J, Ho J, Lam SK et al. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 1982; 82: 864–70.
88. Soutar RL, Coghill SB. Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro. Gastroenterology 1986; 91 (1): 84–93.
89. Konturek SJ, Dembinski A, Warzecha Z et al. Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats. Gut 1988; 29 (7): 894–902.
90. Slomiany BL, Nishikawa H, Bilski J, Slomiany A. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Am J Gastroenterol 1990; 85 (4): 390–3.
91. Konturek JW, Brzozowski T, Konturek SJ. Epidermal growth factor in protection, repair, and healing of gastroduodenal mucosa. J Clin Gastroenterol 1991; 13 (Suppl. 1): S88–97.
92. Konturek JW, Brzozowski T, Konturek SJ. Epidermal growth factor in protection, repair, and healing of gastroduodenal mucosa. J Clin Gastroenterol 1991; 13 (Suppl. 1): S88–97.
93. Eleftheriadis E, Kotzampassi K, Tzartinoglou E et al. Colloidal bismuth subcitrate-induced changes on gastric mucosal hemodynamics in the rat: gastric mucosal blood flow after CBS treatment. Gastroenterol Jpn 1991; 26 (3): 283–6.
94. Bagchi D, McGinn TR, Ye X et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci 1999; 44 (12): 2419–28.
95. Bagchi D, Carryl OR, Tran MX et al. Protection against chemically-induced oxidative gastrointestinal tissue injury in rats by bismuth salts. Dig Dis Sci 1997; 42 (9): 1890–900.
96. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88 (4): 1547–65.
97. Ahmed A, Salmon PR, Cairns CR et al. Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate. Gut 1992; 33 (2): 159–63.
98. Rokkas T, Pursey C, Uzoechina E et al. Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29 (10): 1386–91.
99. Loffeld RJ, Potters HV, Stobberingh E et al. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut 1989; 30 (9): 1206–12.
100. Kang JY, Tay HH, Wee A, Guan R et al. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 1990; 31 (4): 476–80.
101. Goh KL, Parasakthi N, Peh SC et al. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26 (11): 1123–31.
102. Vaira D, Holton J, Ainley C et al. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia. Ital J Gastroenterol 1992; 24 (7): 400–4.
103. Fischbach LA, Correa P, Ramirez H et al. Anti-inflammatory and tissue protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Aliment Pharmacol Ther 2001; 15 (6): 831–41.
104. Kononov A.V., Mozgovoi S.I., Rybkina L.B. i dr. Otsenka tsitoprotektivnogo vliianiia vismuta trikaliia ditsitrata na slizistuiu obolochku zheludka pri eradikatsii H. pylori. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2014; 24 (6): 21–8. [in Russian]
105. Rybkina L.B., Nazarov A.N., Vladimirova A.V. Kliniko-morfologicheskoe obosnovanie prodolzhennoi terapii preparatom vismuta trikaliia ditsitratom pri khronicheskom Helicobacter pylori-assotsiirovannom gastrite s sindromom dispepsii. Molodoi uchenyi. 2015; 22 (102): 285–95. [in Russian]
106. Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
107. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep 2011; 16 (1): 1–7.
108. Kalisperati P, Spanou E, Pateras IS et al. Inflammation, DNA damage, Helicobacter pylori and gastric tumorigenesis. Front Genet 2017; 8: 20. DOI: 10.3389/fgene.2017.00020
109. Kononov A.V. Rol' patologoanatomicheskogo zakliucheniia "Khronicheskii gastrit" v sisteme personifitsirovannoi kantserpreventsii. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2018; 28 (4): 91–101. [in Russian]
110. Lee SP. The mode of action of colloidal bismuth subcitrate. Scand J Gastroenterol Suppl 1991; 185: 1–6.
111. Beil W, Bierbaum S, Sewing KF. Studies on the mechanism of action of colloidal bismuth subcitrate. II. Interaction with pepsin. Pharmacology 1993; 47 (2): 141–4.
112. Baron JH, Barr J, Batten J et al. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Gut 1986; 27 (5): 486–90.
113. Marshall BJ, Armstrong JA, Francis GJ et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987; 37 (Suppl. 2): 16–30.
114. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65 (5): 870–8.
115. Goodwin CS, Armstrong JA, Cooper M. Colloidal bismuth subcitrate inhibits the adherence of H. pylori to epithelial cells. Ital J Gastroenterology 1991; 23 (Suppl. 2): 40.
116. Maev I.V., Ku­cheriavyi Yu.A., Andreev D.N. Aktual'nye vozmozhnosti optimizatsii antikhelikobakternoi terapii. Lechashchii vrach. 2014; 4: 73–9. [in Russian]
117. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics 2012; 4 (3): 239–43.
118. Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther 2015; 42: 922–33.
119. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection Maastricht V/Florence Consensus Report. Gut 2016; 66: 6–30.
120. Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther 2016; 14 (6): 577–85.
121. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017; e12392.
122. Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther 2018; 16 (9): 679–87.
123. Ivashkin V.T., Maev I.V., Lapina T.L. Rekomendatsii Rossiiskoi Gastroenterologicheskoi Assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii i koloproktologii. 2012; 22 (1): 87–9. [in Russian]
124. Lazebnik L.B., Tkachenko E.I., Abdulganieva D.I. i dr. VI Natsional'nye rekomendatsii po diagnostike i lecheniiu kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (VI Moskovskie soglasheniia). Eksperim. i klin. gastroenterologiia. 2017; 2 (138): 3–21. [in Russian]
125. Sun H. Biological Chemistry of Arsenic, Antimony and Bismuth. USA, NJ: John Wiley & Sons: Hoboken, 2011.

А.А.Самсонов1, Н.Н.Голубев*2, Н.Г.Андреев1, Н.А.Щербакова1

1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБУ «Поликлиника №3» Управления делами Президента Российской Федерации. 129090, Россия, Москва, пер. Грохольский, д. 31
*nngolubev@mail.ru

________________________________________________

А.А.Samsonov1, N.N.Golubev*2, N.G.Andreev1, N.A.Shcherbakova1

1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 Polyclinic №3 General Management Department of the Presidential Administration of the President of Russian Federation. 129090, Russian Federation, Moscow, per. Grokhol'skii, d. 31
*nngolubev@mail.ru